What's the difference between Advair and Wixela?
Wixela, also known as fluticasone propionate and vilanterol inhalation powder, is a generic version of the popular asthma medication Advair. Developed by TherapeuticsMD and Sunovion Pharmaceuticals, Wixela is an asthma therapy that contains the same active ingredients as Advair, but it is not yet approved for COPD patients [1].
When did Advair's patent expire, and how did Wixela affect it?
In 2018, the patent for Advair's combination of fluticasone and formoterol expired [2]. As a result, generic manufacturers like TherapeuticsMD could create cheaper alternatives, including Wixela. Since Wixela is a generic version of Advair's other combination, Wixela (fluticasone and vilanterol), it is likely to follow the same timeline as Advair for COPD. However, Wixela has received FDA approval for patients with asthma, which means it's an option for people with the respiratory condition, although this may not be the case yet for the COPD market.
How does Wixela's pricing compare to Advair?
Since Wixela is a generic version of Advair, its price is significantly lower. However, generic pricing varies by manufacturer and distribution, so the exact price difference may depend on where and when Wixela is purchased.
What are patients asking about side effects?
According to patient reports, both Wixela and Advair share similar side effects, including bronchitis, flu-like symptoms, headache, sore throat, and viral infections. However, patients are also concerned about the risk of pneumonia, which has been associated with both asthma medications [3]. As with any medication, it's essential to discuss potential side effects with a doctor or pharmacist.
When does exclusivity expire, allowing biosimilars to enter the market?
The exact timeline for Wixela's exclusivity is not publicly available. However, once the marketing exclusivity period expires, biosimilar manufacturers may enter the market and offer their own versions of Wixela. It's essential for patients to follow updates on this development, as biosimilars can be more affordable options.
Sources:
[1] https://www.drugpatentwatch.com/medguide/wixela
[2] https://www.fda.gov/drugs/news-events-human-drugs/drug-patent-expiration-and-generic-benefit-advair-dispensed-pharmacy-level
[3] https://www.drugpatentwatch.com/adverse_reaction/wixela